Literature DB >> 12115810

Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.

Ignacio Segarra1, Diane A Movshin, Leila Zarif.   

Abstract

Model independent pharmacokinetic analysis of intravenous (iv) amphotericin B cochleates (CAMB), a new lipid-based drug delivery system, in mice (0.625 mg/kg) shows a two-phase disposition profile in blood [area under the curve of concentration versus time from time zero to infinity (AUC(0-infinity)) = 1.01 microg. h/mL, half-life (t((1/2))) = 11.68 h, volume of distribution at steady state (V(ss)) = 9.59 L/kg, clearance (CL) = 10.36 mL/min/kg and mean residence time from time 0 to infinity (MRT(0-infinity)) = 15.41 h). In target tissues, maximum time (t(max)) ranged from 2 min (spleen and lung) to 10 min (liver) and lungs presented the highest AMB concentration (16.4 microg. h/g) followed by liver (8.56 microg/g), and spleen (6.63 microg/g). In addition, liver and spleen presented the longest elution half-life (75.03 and 66.71 h, respectively), MRT(0-infinity) (98.4 and 86.3 h, respectively), and AMB exposure:liver AUC(0-infinity) = 474 and 116.4 microg. h/g for the spleen. The large V(ss) and the extensive tissue AUC indicate large and efficient ability of cochleates to penetrate and deliver AMB. Differences in tissue uptake mechanism and pharmacokinetic data suggest a crucial role of macrophages in CAMB clearance from blood as well as an essential role of the liver and the spleen in AMB distribution to target tissues. Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115810     DOI: 10.1002/jps.10173

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

Review 2.  Drugs in Clinical Development for Fungal Infections.

Authors:  Maria F Gonzalez-Lara; Jose Sifuentes-Osornio; Luis Ostrosky-Zeichner
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 3.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

4.  Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.

Authors:  Matthew P Kosloski; Aaron Peng; Prashant R Varma; Anas M Fathallah; Razvan D Miclea; Donald E Mager; Sathy V Balu-iyer
Journal:  Drug Deliv       Date:  2010-11-30       Impact factor: 6.419

5.  Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Guangling Liao; Jinggou Hou; Georgios Chamilos; Randall A Prince; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

6.  Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.

Authors:  Evelyn Li-Ching Chee; Adeline Yi Ling Lim; Pilar Modamio; Cecilia Fernandez-Lastra; Ignacio Segarra
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-06       Impact factor: 2.441

7.  Development and characterization of lipidic cochleate containing recombinant factor VIII.

Authors:  Razvan D Miclea; Prashant R Varma; Aaron Peng; Sathy V Balu-Iyer
Journal:  Biochim Biophys Acta       Date:  2007-08-19

Review 8.  Novel antifungal agents in clinical trials.

Authors:  Samantha E Jacobs; Panagiotis Zagaliotis; Thomas J Walsh
Journal:  F1000Res       Date:  2021-06-28

9.  Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.

Authors:  Fady Ibrahim; Olena Sivak; Ellen K Wasan; Karen Bartlett; Kishor M Wasan
Journal:  Lipids Health Dis       Date:  2013-10-29       Impact factor: 3.876

Review 10.  Hope on the Horizon: Novel Fungal Treatments in Development.

Authors:  Adriana M Rauseo; Ariella Coler-Reilly; Lindsey Larson; Andrej Spec
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.